一种用于治疗颈部肌张力障碍和眼睑痉挛的新型肉毒杆菌毒素（Xeomin）。
A new botulinum toxin (Xeomin) for cervical dystonia and blepharospasm.
出版信息
Med Lett Drugs Ther. 2010 Nov 15;52(1351):90-1.
PMID:21068703
Abstract
The FDA has approved incobotulinumtoxinA (Xeomin--Merz) for treatment of cervical dystonia and blepharospasm in adults. It has been commercially available in Germany since 2005. Several formulations of botulinum toxin type A (Botox; Dysport) and type B (Myobloc) are already marketed for treatment of cervical dystonia. Botox is also approved for treatment of blepharospasm.
摘要
美国食品药品监督管理局（FDA）已批准incobotulinumtoxinA（Xeomin - 默克公司）用于治疗成人颈部肌张力障碍和眼睑痉挛。自2005年起，它已在德国上市销售。几种A型肉毒杆菌毒素制剂（保妥适；Dysport）和B型肉毒杆菌毒素制剂（Myobloc）已被用于治疗颈部肌张力障碍。保妥适也被批准用于治疗眼睑痉挛。
Zotero 插件